Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9NUV9
UPID:
GIMA4_HUMAN
Alternative names:
Immunity-associated nucleotide 1 protein; Immunity-associated protein 4
Alternative UPACC:
Q9NUV9
Background:
GTPase IMAP family member 4, also known as Immunity-associated nucleotide 1 protein and Immunity-associated protein 4, plays a crucial role in thymocyte development. It is a GTPase with a higher affinity for GDP than GTP, suggesting a unique regulatory mechanism in cellular processes.
Therapeutic significance:
Understanding the role of GTPase IMAP family member 4 could open doors to potential therapeutic strategies.